CCND1

Summary

CCND1 (cyclin D1, HGNC:1582) is a protein-coding gene on chromosome 11q13.3, encoding G1/S-specific cyclin-D1 (P24385). Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. In precision oncology, CCND1 Overexpression confers sensitivity to Palbociclib in Mantle Cell Lymphoma (CIViC Level B); 11 further curated variant–drug associations are listed below. It is a selective cancer dependency (DepMap: 72.8% of cell lines).

The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of human cancers.

Source: NCBI Gene 595 — RefSeq curated summary.

At a glance

• Gene–disease (curated): von Hippel-Lindau disease (Supportive, GenCC)
• GWAS associations: 45
• Clinical variants (ClinVar): 50 total — 1 likely-pathogenic
• Phenotypes (HPO): 94
• Druggable target: yes — 35 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 12 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 3 cancer types
• Cancer dependency (DepMap): dependent in 72.8% of screened cell lines
• MANE Select transcript: NM_053056

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1582
Approved symbol	CCND1
Name	cyclin D1
Location	11q13.3
Locus type	gene with protein product
Status	Approved
Aliases	U21B31
Ensembl gene	ENSG00000110092
Ensembl biotype	protein_coding
OMIM	168461
Entrez	595

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 retained_intron, 3 protein_coding

ENST00000227507, ENST00000535993, ENST00000536559, ENST00000539241, ENST00000542367, ENST00000545484, ENST00000913508

RefSeq mRNA: 1 — MANE Select: NM_053056 NM_053056

CCDS: CCDS8191

Canonical transcript exons

ENST00000227507 — 5 exons

Exon	Start	End
ENSE00000737399	69643832	69643991
ENSE00000894873	69651118	69654474
ENSE00000894874	69647994	69648142
ENSE00001330774	69641156	69641511
ENSE00003684720	69643031	69643246

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 99.09.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 255.2715 / max 2937.0464, expressed in 1665 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115593	242.0613	1663
115605	4.1781	1006
115607	2.3996	821
115601	1.9747	632
115596	1.0705	562
115599	0.9475	455
115597	0.7044	425
115606	0.5764	294
115598	0.5189	274
115604	0.4939	252

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	99.09	gold quality
stromal cell of endometrium	CL:0002255	98.30	gold quality
upper arm skin	UBERON:0004263	97.20	gold quality
esophagus squamous epithelium	UBERON:0006920	97.00	gold quality
upper leg skin	UBERON:0004262	96.62	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.57	gold quality
sural nerve	UBERON:0015488	96.44	gold quality
epithelium of esophagus	UBERON:0001976	96.30	gold quality
squamous epithelium	UBERON:0006914	96.19	gold quality
gingival epithelium	UBERON:0001949	96.07	gold quality
nipple	UBERON:0002030	96.05	gold quality
lower esophagus mucosa	UBERON:0035834	95.92	gold quality
tibia	UBERON:0000979	95.86	gold quality
esophagus mucosa	UBERON:0002469	95.42	gold quality
gingiva	UBERON:0001828	95.38	gold quality
hair follicle	UBERON:0002073	95.36	gold quality
skin of abdomen	UBERON:0001416	95.32	gold quality
palpebral conjunctiva	UBERON:0001812	95.04	gold quality
zone of skin	UBERON:0000014	94.77	gold quality
right coronary artery	UBERON:0001625	94.72	gold quality
oral cavity	UBERON:0000167	94.50	gold quality
skin of leg	UBERON:0001511	94.45	gold quality
cervix squamous epithelium	UBERON:0006922	94.37	silver quality
penis	UBERON:0000989	94.28	gold quality
caput epididymis	UBERON:0004358	94.01	gold quality
skin of hip	UBERON:0001554	93.86	gold quality
apex of heart	UBERON:0002098	93.80	gold quality
prostate gland	UBERON:0002367	93.65	gold quality
mammalian vulva	UBERON:0000997	93.57	gold quality
ascending aorta	UBERON:0001496	93.56	gold quality

Single-cell (SCXA)

Detected in 27 experiment(s), a significant marker in 22.

Experiment	Marker?	Max mean expression
E-HCAD-56	yes	1554.38
E-GEOD-114530	yes	1268.72
E-GEOD-124472	yes	1081.95
E-MTAB-10283	yes	675.46
E-MTAB-10485	yes	671.98
E-GEOD-93593	yes	532.27
E-CURD-79	yes	518.04
E-MTAB-8894	yes	482.46
E-GEOD-124858	yes	481.58
E-MTAB-8205	yes	364.93
E-GEOD-75140	yes	223.01
E-CURD-114	yes	54.78
E-HCAD-10	yes	26.84
E-HCAD-1	yes	22.10
E-GEOD-81547	yes	22.05

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
MSI1	Activation

Upstream regulators (CollecTRI, top): AHR, AP1, APP, AR, ATF2, ATF3, ATF4, BARX2, BCL3, BCL6, BHLHE40, BHLHE41, BRCA1, BRD4, BTG2, CDX1, CDX2, CEBPA, CEBPB, CEBPD, CLU, CREB1, CREM, CTCF, CTNNB1, CTNNBL1, DDRGK1, DKK1, DNMT3A, E2F1, E2F4, E2F8, E4F1, EGR1, ELK3, ENO1, EP300, ESR1, ESR2, ETS1

miRNA regulators (miRDB)

184 targeting CCND1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 72.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• expression is related to apoptosis in thymus (PMID:11642719)
• TGFbeta and PTHrP control chondrocyte proliferation by activating cyclin D1 expression (PMID:11739785)
• The ability of p21(Cip1) to inhibit cyclin D1 nuclear export correlates with its ability to bind to Thr-286-phosphorylated cyclin D1 and thereby prevents cyclin D1.CRM1 association (PMID:11751903)
• Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. (PMID:11815623)
• Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid adenomas (PMID:11836555)
• TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins. (PMID:11838966)
• Lower expression of p16 protein and overexpression of Cyclin D1 protein may be considered as prognostic biomarkers to skin carcinogenesis. (PMID:11860939)
• Cyclin D1 play important roles in esophageal carcinogenesis. (PMID:11870667)
• This study was conducted to explore the association between the polymorphism and the susceptibility to and disease status of TCC of the bladder in 222 cases and 317 native Japanese controls (PMID:11872630)
• Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4 (PMID:11884610)
• cyclin D1 may be a target gene for prolactin in normal lobuloalveolar development, as well as in the development and/or progression of mammary cancer. (PMID:11923474)
• analysis of expression improves differentiation of mantle cells from other lymphoma cells (PMID:11935308)
• Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. (PMID:11948404)
• A/G polymorphism of CCND1 was associated with the susceptibility to NPC (PMID:11958128)
• expression affected by estrogen receptors alpha and beta (PMID:11986316)
• Activation of cyclin D1 and D2 promoters by human T-cell leukemia virus type I tax protein is associated with IL-2-independent growth of T cells (PMID:11992406)
• The expression of MIB-1 and prognosis in cyclin D1(CyD1)+ and CyD1- mantle cell lymphoma (MCL)were studied and compared to B-CLL/SLL. The CyD1- group (nodal MCL and CLL/SLL) had a longer median survival time than the CyD1+ group (nodal MCL and MLP). (PMID:12002755)
• Overexpression of cyclin D1 is found to be significantly correlated with increased chromosomal instability in patients with breast cancer. (PMID:12007188)
• The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation (RASSF1A) (PMID:12024041)
• VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. (PMID:12036906)
• Cyclin D1 is a candidate oncogene in cutaneous melanoma. (PMID:12036934)
• Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin. (PMID:12036951)
• cyclin D1 is a novel ligand-independent co-repressor (PMID:12048199)
• Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. (PMID:12067972)
• The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. (PMID:12096344)
• Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. (PMID:12097293)
• regulates cell cycle (PMID:12101670)
• Cyclin D1 expression in peripheral blood of 7 mantle-cell lymphoma pts was 1305.4 times higher than in 24 chronic B-cell lymphocytic leukemia pts. (PMID:12127555)
• Data suggest that one mechanism by which INI1/hSNF5 exerts its tumor suppressor function is by mediating the cell cycle arrest due to the direct recruitment of HDAC activity to the cyclin D1 promoter, causing its repression and G(0)-G(1) arrest. (PMID:12138206)
• overexpression of cyclin D1 sensitizes MCF7 cells to treatment with taxol (PMID:12150453)
• These data suggest that PKCdelta attenuates cyclin D1 promoter activity via the regulation of three distinct cis-acting regulatory elements. (PMID:12151312)
• The CCND1 gene was rarely amplified in ILC in spite of showing overexpression of the protein in 41% of tumors. Hence, unlike IDC, increase in gene dosage did not account for the protein excess. (PMID:12203362)
• upregulation of cyclin D1 and Fra-1 in human colorectal adenocarcinomas is driven by abnormally expressed beta-catenin (PMID:12209953)
• Strong cyclin D1 mRNA overexpression was detected in mantle cell lymphomas, hairy cell leukemias,and multiple myelomas. Intermediate transcript levels were found in some multiple myelomas and hairy cell leukemias. (PMID:12231535)
• Amplifications of c-myc and CCND1 are associated with detrusor-muscle-invasive transitional cell carcinoma (PMID:12237776)
• inhibition of GSK3beta activity appears to trigger nuclear accumulation of cyclin D1 and cell cycle progression (PMID:12364325)
• early use of oral contraceptives may be associated with subset of mammary tumors that overexpress cyclin D1 (PMID:12376514)
• Marked intratumoral heterogeneity of c-myc and this but not of c-erbB2 amplification in breast cancer (PMID:12379776)
• These results indicate that estrogen-induced cyclin D(1) transcription can occur in HepG2 cells independently of the transcriptional activity of estrogen receptor. (PMID:12388769)
• Oct-1 potentiates CREB-dependent cyclin D1 transcriptional activity by a phospho-CREB and CREB binding protein-independent mechanism (PMID:12391146)

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccnd1	ENSDARG00000101637
mus_musculus	Ccnd1	ENSMUSG00000070348
rattus_norvegicus	Ccnd1	ENSRNOG00000020918
drosophila_melanogaster	CycA	FBGN0000404
drosophila_melanogaster	CycB	FBGN0000405
drosophila_melanogaster	CycD	FBGN0010315
drosophila_melanogaster	CycE	FBGN0010382
caenorhabditis_elegans		WBGENE00000863
caenorhabditis_elegans		WBGENE00000864
caenorhabditis_elegans		WBGENE00000865
caenorhabditis_elegans		WBGENE00000866
caenorhabditis_elegans	cyb-2.2	WBGENE00000867
caenorhabditis_elegans		WBGENE00000870
caenorhabditis_elegans	cye-1	WBGENE00000871
caenorhabditis_elegans		WBGENE00017259

Paralogs (18): CCNE1 (ENSG00000105173), CCNP (ENSG00000105219), CCNJ (ENSG00000107443), CCND3 (ENSG00000112576), CCNG1 (ENSG00000113328), CCNI (ENSG00000118816), CCND2 (ENSG00000118971), CCNA1 (ENSG00000133101), CCNB1 (ENSG00000134057), CCNJL (ENSG00000135083), CCNG2 (ENSG00000138764), CCNA2 (ENSG00000145386), CCNB3 (ENSG00000147082), CCNO (ENSG00000152669), CCNB2 (ENSG00000157456), CCNF (ENSG00000162063), CCNE2 (ENSG00000175305), CCNI2 (ENSG00000205089)

Protein

Protein identifiers

G1/S-specific cyclin-D1 — P24385 (reviewed: P24385)

Alternative names: B-cell lymphoma 1 protein, BCL-1 oncogene, PRAD1 oncogene

All UniProt accessions (3): P24385, F5H437, Q6FI00

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also a substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.

Subunit / interactions. Interacts with either CDK4 or CDK6 protein kinase to form a serine/threonine kinase holoenzyme complex. The cyclin subunit imparts substrate specificity to the complex. Component of the ternary complex CCND1/CDK4/CDKN1B required for nuclear translocation and modulation of CDK4-mediated kinase activity. Interacts directly with CDKN1B. Can form similar complexes with either CDKN1A or CDKN2A. Interacts with UHRF2; the interaction ubiquitinates CCND1 and appears to occur independently of phosphorylation. Interacts with USP2. Interacts (via cyclin N-terminal domain) with INSM1 (via N-terminal region); the interaction competes with the binding of CCND1 to CDK4 during cell cycle progression and inhibits CDK4 activity. Interacts with CDK4; the interaction is prevented with the binding of CCND1 to INSM1 during cell cycle progression. Interacts with FBXO32; this interaction mediates CCND1 stabilization via ‘Lys-27’-linked polyubiquitination.

Subcellular location. Nucleus. Cytoplasm. Nucleus membrane.

Post-translational modifications. Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation by the DCX(AMBRA1) complex. It also plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex following DNA damage. Ubiquitinated at Lys-269 by the DCX(AMBRA1) complex during the transition from G1 to S cell phase, leading to its degradation: ubiquitination is dependent on Thr-286 phosphorylation. The DCX(AMBRA1) complex represents the major regulator of CCND1 stability during the G1/S transition. Also ubiquitinated by the SCF(FBXO4) and Cul7-RING(FBXW8) ubiquitin-protein ligase complexes. Following DNA damage it is ubiquitinated by the SCF(FBXO31) protein ligase complex. SCF(FBXO31) ubiquitination is dependent on Thr-286 phosphorylation. Ubiquitinated also by UHRF2 apparently in a phosphorylation-independent manner. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to its stabilization. Ubiquitinated by FBXO32 at Lys-58 via ‘Lys27’-linked polyubiquitination; leading to its stabilization.

Disease relevance. A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle. A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer. Multiple myeloma (MM) [MIM:254500] A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.

Similarity. Belongs to the cyclin family. Cyclin D subfamily.

RefSeq proteins (1): NP_444284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004367	Cyclin_C-dom	Domain
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR039361	Cyclin	Family
IPR048258	Cyclins_cyclin-box	Conserved_site

Pfam: PF00134, PF02984

UniProt features (37 total): helix 17, turn 5, sequence conflict 3, mutagenesis site 3, strand 2, cross-link 2, chain 1, domain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
9CSK	X-RAY DIFFRACTION	2.25
2W96	X-RAY DIFFRACTION	2.3
6P8E	X-RAY DIFFRACTION	2.3
2W9Z	X-RAY DIFFRACTION	2.45
5VZU	X-RAY DIFFRACTION	2.7
2W99	X-RAY DIFFRACTION	2.8
6P8G	X-RAY DIFFRACTION	2.8
2W9F	X-RAY DIFFRACTION	2.85
6P8F	X-RAY DIFFRACTION	2.89
6P8H	X-RAY DIFFRACTION	3.19
9IVD	ELECTRON MICROSCOPY	3.55

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P24385-F1	87.31	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 286, 58, 269

Mutagenesis-validated functional residues (3):

Position	Phenotype
286–288	reduced ubiquitination and subsequent degradation by the proteasome.
286	reduced interaction with the dcx(ambra1) complex, and subsequent ubiquitination and degradation by the proteasome. aboli
287	reduced interaction with the dcx(ambra1) complex, and subsequent ubiquitination and degradation by the proteasome.

Function

Pathways and Gene Ontology

Reactome pathways

51 pathways

ID	Pathway
R-HSA-187577	SCF(Skp2)-mediated degradation of p27/p21
R-HSA-1912408	Pre-NOTCH Transcription and Translation
R-HSA-3214858	RMTs methylate histone arginines
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-69231	Cyclin D associated events in G1
R-HSA-75815	Ubiquitin-dependent degradation of Cyclin D
R-HSA-8849470	PTK6 Regulates Cell Cycle
R-HSA-8853884	Transcriptional Regulation by VENTX
R-HSA-8878166	Transcriptional regulation by RUNX2
R-HSA-8934593	Regulation of RUNX1 Expression and Activity
R-HSA-8951430	RUNX3 regulates WNT signaling
R-HSA-8951936	RUNX3 regulates p14-ARF
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling
R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
R-HSA-9754119	Drug-mediated inhibition of CDK4/CDK6 activity
R-HSA-9825892	Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
R-HSA-9929491	SPOP-mediated proteasomal degradation of PD-L1(CD274)
R-HSA-1266738	Developmental Biology
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-157118	Signaling by NOTCH
R-HSA-162582	Signal Transduction
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-168256	Immune System
R-HSA-1912422	Pre-NOTCH Expression and Processing
R-HSA-212436	Generic Transcription Pathway
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-449147	Signaling by Interleukins
R-HSA-453279	Mitotic G1 phase and G1/S transition

MSigDB gene sets: 1002 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, RNGTGGGC_UNKNOWN, REACTOME_SIGNALING_BY_NOTCH, GOBP_RESPONSE_TO_ETHANOL, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_EPITHELIUM_DEVELOPMENT, WALLACE_PROSTATE_CANCER_RACE_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_REGULATION_OF_MAMMARY_GLAND_EPITHELIAL_CELL_PROLIFERATION, PID_TELOMERASE_PATHWAY, GOBP_RESPONSE_TO_ESTRADIOL, SWEET_KRAS_ONCOGENIC_SIGNATURE

GO Biological Process (42): G1/S transition of mitotic cell cycle (GO:0000082), negative regulation of transcription by RNA polymerase II (GO:0000122), re-entry into mitotic cell cycle (GO:0000320), DNA damage response (GO:0006974), lactation (GO:0007595), response to xenobiotic stimulus (GO:0009410), response to iron ion (GO:0010039), response to X-ray (GO:0010165), positive regulation of G2/M transition of mitotic cell cycle (GO:0010971), Wnt signaling pathway (GO:0016055), neuron differentiation (GO:0030182), negative regulation of epithelial cell differentiation (GO:0030857), endoplasmic reticulum unfolded protein response (GO:0030968), mitotic G1 DNA damage checkpoint signaling (GO:0031571), response to magnesium ion (GO:0032026), response to estradiol (GO:0032355), response to vitamin E (GO:0033197), Leydig cell differentiation (GO:0033327), mammary gland epithelial cell proliferation (GO:0033598), positive regulation of mammary gland epithelial cell proliferation (GO:0033601), negative regulation of neuron apoptotic process (GO:0043524), response to estrogen (GO:0043627), response to leptin (GO:0044321), fat cell differentiation (GO:0045444), response to ethanol (GO:0045471), cell division (GO:0051301), response to corticosterone (GO:0051412), response to calcium ion (GO:0051592), mammary gland alveolus development (GO:0060749), response to UV-A (GO:0070141), cellular response to hypoxia (GO:0071456), liver regeneration (GO:0097421), positive regulation of G1/S transition of mitotic cell cycle (GO:1900087), liver development (GO:0001889), cell population proliferation (GO:0008283), positive regulation of cell population proliferation (GO:0008284), animal organ regeneration (GO:0031100), response to steroid hormone (GO:0048545), response to glucocorticoid (GO:0051384), regulation of cell cycle (GO:0051726)

GO Molecular Function (12): transcription corepressor activity (GO:0003714), protein kinase activity (GO:0004672), cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), enzyme binding (GO:0019899), protein kinase binding (GO:0019901), histone deacetylase binding (GO:0042826), protein serine/threonine kinase activator activity (GO:0043539), protein-containing complex binding (GO:0044877), cyclin-dependent protein serine/threonine kinase activator activity (GO:0061575), proline-rich region binding (GO:0070064), protein binding (GO:0005515), kinase activity (GO:0016301)

GO Cellular Component (12): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), microtubule organizing center (GO:0005815), cytosol (GO:0005829), bicellular tight junction (GO:0005923), transcription repressor complex (GO:0017053), nuclear membrane (GO:0031965), cyclin D1-CDK4 complex (GO:0097128), cyclin D1-CDK6 complex (GO:0097131), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-18 pathways:

Category	Pathways
Generic Transcription Pathway	2
Transcriptional regulation by RUNX3	2
Cyclin E associated events during G1/S transition	1
Cyclin A:Cdk2-associated events at S phase entry	1
Pre-NOTCH Expression and Processing	1
Chromatin modifying enzymes	1
Signaling by Interleukins	1
G1 Phase	1
S Phase	1
Signaling by PTK6	1
Transcriptional regulation by RUNX1	1
ESR-mediated signaling	1
Extra-nuclear estrogen signaling	1
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1
Cyclin D associated events in G1	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
negative regulation of DNA-templated transcription	2
response to metal ion	2
cell differentiation	2
response to oxygen-containing compound	2
cyclin-dependent protein serine/threonine kinase activity	2
protein binding	2
binding	2
cyclin-dependent protein kinase holoenzyme complex	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
cell cycle process	1
cellular response to stress	1
body fluid secretion	1
mammary gland development	1
milk ejection reflex	1
response to chemical	1
response to ionizing radiation	1
G2/M transition of mitotic cell cycle	1
regulation of G2/M transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of cell cycle G2/M phase transition	1
cell surface receptor signaling pathway	1
generation of neurons	1
epithelial cell differentiation	1
regulation of epithelial cell differentiation	1
negative regulation of cell differentiation	1
cellular response to unfolded protein	1
response to endoplasmic reticulum stress	1
intracellular signal transduction	1
mitotic G1 phase	1
mitotic DNA damage checkpoint signaling	1
mitotic G1/S transition checkpoint signaling	1
response to lipid	1
response to vitamin	1
developmental process involved in reproduction	1
male gonad development	1

Protein interactions and networks

STRING

7562 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCND1	CDK4	P11802	999
CCND1	CDK2	P24941	998
CCND1	CDK6	Q00534	998
CCND1	CDKN1A	P38936	996
CCND1	CDKN1B	P46527	992
CCND1	CDK1	P06493	984
CCND1	ESR1	P03372	972
CCND1	BCL2	P10415	958
CCND1	MYC	P01106	951
CCND1	CCNL2	Q96S94	950
CCND1	CDKN2A	P42771	947
CCND1	TP53	P04637	928
CCND1	CTNNB1	P35222	926
CCND1	AKT1	P31749	919
CCND1	IGHV4-38-2	P0DP08	909

IntAct

196 interactions, top by confidence:

A	B	Type	Score
CDK4	CCND1	psi-mi:“MI:0915”(physical association)	0.990
CCND1	CDK4	psi-mi:“MI:0915”(physical association)	0.990
CCND1	CDK4	psi-mi:“MI:0407”(direct interaction)	0.990
CDK4	CCND1	psi-mi:“MI:0914”(association)	0.990
CCND1	CDK4	psi-mi:“MI:2364”(proximity)	0.990
CCND1	CDK4	psi-mi:“MI:0403”(colocalization)	0.990
CCND1	CDK4	psi-mi:“MI:0914”(association)	0.990
CDK4	CCND1	psi-mi:“MI:0407”(direct interaction)	0.990

BioGRID (570): CCND1 (Affinity Capture-Western), CCND1 (Reconstituted Complex), CDK4 (Two-hybrid), CDKN1A (Two-hybrid), CDKN1B (Two-hybrid), CCND1 (Affinity Capture-RNA), EP300 (Affinity Capture-Western), CCND1 (Affinity Capture-Western), BCAS3 (Two-hybrid), CDH13 (Two-hybrid), KLK7 (Two-hybrid), KLK9 (Two-hybrid), CCND1 (Two-hybrid), CCND1 (Two-hybrid), SLC25A5 (Affinity Capture-MS)

ESM2 similar proteins: A5PK16, O08918, O42575, O96020, P24385, P24864, P25322, P30279, P30280, P30282, P39948, P39949, P39950, P41002, P47794, P48961, P49706, P49707, P50755, P50756, P51944, P51945, P51959, P53782, P55169, Q04827, Q0P5D3, Q16589, Q2KI22, Q32NJ2, Q32NM1, Q52QT8, Q5E9I1, Q5E9K7, Q5R5D0, Q5R6J5, Q5SRT8, Q5T5M9, Q5XGG5, Q61457

Diamond homologs: A0MEB5, O01501, O15995, O42575, O48790, O77689, O93229, O95067, O96020, P04962, P07818, P13350, P13351, P13952, P14785, P15206, P18606, P20248, P20439, P24385, P24861, P24862, P24864, P25010, P25011, P25012, P25322, P29332, P30183, P30274, P30276, P30277, P30278, P34638, P34800, P34801, P37881, P37882, P37883, P39948

SIGNOR signaling

70 interactions.

A	Effect	B	Mechanism
MYC	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
CCND1	up-regulates	HDAC2	binding
CCND1	up-regulates	HDAC3	binding
HDAC1	up-regulates	CCND1	binding
HDAC2	up-regulates	CCND1	binding
CTNNB1	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
ESR1	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
NCOA3	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
CHUK	down-regulates	CCND1	phosphorylation
GSK3B	down-regulates	CCND1	phosphorylation
CYLD	up-regulates	CCND1
DYRK1B	down-regulates	CCND1	phosphorylation
GLI3	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
CCND1	“up-regulates quantity by expression”	MSI1	“transcriptional regulation”
CCND1	up-regulates	NOTCH1
MAPK14	up-regulates	CCND1	phosphorylation
SRPK2	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
GLI1	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
palbociclib	down-regulates	CCND1	“chemical inhibition”
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide	down-regulates	CCND1	“chemical inhibition”
TEAD1	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
CCND1	up-regulates	CDK4	binding
DYRK1A	down-regulates	CCND1	phosphorylation
R547	down-regulates	CCND1	“chemical inhibition”
RBPJ/NOTCH	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”
GSK3B	“down-regulates quantity by destabilization”	CCND1	phosphorylation
CCND1	“form complex”	CyclinD1/CDK6	binding
STAT3	“up-regulates quantity by expression”	CCND1	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 90 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	8	72.5×	2e-11
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	6	61.2×	1e-08
p53-Dependent G1 DNA Damage Response	6	61.2×	1e-08
p53-Dependent G1/S DNA damage checkpoint	6	61.2×	1e-08
G1/S DNA Damage Checkpoints	6	57.6×	2e-08
G1 Phase	9	50.6×	2e-11
Aberrant regulation of mitotic cell cycle due to RB1 defects	8	46.6×	3e-10
TP53 Regulates Transcription of Cell Cycle Genes	6	46.6×	7e-08

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of DNA replication	5	35.0×	4e-05
mitotic G2 DNA damage checkpoint signaling	5	26.7×	9e-05
G1/S transition of mitotic cell cycle	10	24.2×	6e-09
regulation of circadian rhythm	7	21.9×	6e-06
positive regulation of miRNA transcription	6	21.0×	4e-05
regulation of mitotic cell cycle	7	20.3×	8e-06
Ras protein signal transduction	8	19.8×	2e-06
regulation of G1/S transition of mitotic cell cycle	5	18.5×	5e-04

Disease & clinical

Cancer significance

From CIViC — curated cancer-variant interpretation:

Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins, and the cyclin-dependent kinases (CDK’s) they activate, have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, but currently there are no FDA-approved targeted therapies.

From intOGen — cancer-driver classification: activating (oncogene-like) across 3 cancer types — HNSC, PCM, UCEC.

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	20
Likely benign	6
Benign	7

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
442080	GRCh37/hg19 11q13.2-13.4(chr11:67799160-70701268)x1	Likely pathogenic

SpliceAI

854 predictions. Top by Δscore:

Variant	Effect	Δscore
11:69641464:G:GT	donor_gain	1.0000
11:69641509:G:GT	donor_gain	1.0000
11:69643831:GC:G	acceptor_gain	1.0000
11:69643831:GCAA:G	acceptor_gain	1.0000
11:69647986:T:A	acceptor_gain	1.0000
11:69647991:CAG:C	acceptor_loss	1.0000
11:69647992:A:AC	acceptor_loss	1.0000
11:69647992:A:AG	acceptor_gain	1.0000
11:69647992:AGAT:A	acceptor_gain	1.0000
11:69647993:G:A	acceptor_loss	1.0000
11:69647993:G:GT	acceptor_gain	1.0000
11:69647993:GA:G	acceptor_gain	1.0000
11:69647993:GAT:G	acceptor_gain	1.0000
11:69647993:GATG:G	acceptor_gain	1.0000
11:69647993:GATGT:G	acceptor_gain	1.0000
11:69648139:CCCG:C	donor_gain	1.0000
11:69648140:CCG:C	donor_gain	1.0000
11:69648141:CG:C	donor_gain	1.0000
11:69648142:GG:G	donor_gain	1.0000
11:69648143:G:GG	donor_gain	1.0000
11:69648143:GTA:G	donor_loss	1.0000
11:69648144:T:A	donor_loss	1.0000
11:69651113:CTCA:C	acceptor_loss	1.0000
11:69651116:A:AG	acceptor_gain	1.0000
11:69651116:AG:A	acceptor_gain	1.0000
11:69651116:AGG:A	acceptor_loss	1.0000
11:69651117:G:GC	acceptor_loss	1.0000
11:69651117:G:GG	acceptor_gain	1.0000
11:69651117:GG:G	acceptor_gain	1.0000
11:69651117:GGACT:G	acceptor_gain	1.0000

AlphaMissense

1940 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:69641500:T:A	W63R	1.000
11:69641500:T:C	W63R	1.000
11:69641502:G:C	W63C	1.000
11:69641502:G:T	W63C	1.000
11:69643092:G:C	R87P	1.000
11:69643139:G:T	G103W	1.000
11:69643140:G:A	G103E	1.000
11:69643150:C:G	C106W	1.000
11:69643161:C:A	A110D	1.000
11:69643163:T:C	S111P	1.000
11:69643164:C:T	S111F	1.000
11:69643168:G:C	K112N	1.000
11:69643168:G:T	K112N	1.000
11:69643203:T:C	L124P	1.000
11:69643865:T:A	W150R	1.000
11:69643865:T:C	W150R	1.000
11:69641483:G:C	R57P	0.999
11:69641492:T:A	V60D	0.999
11:69641494:G:C	A61P	0.999
11:69641495:C:A	A61D	0.999
11:69641501:G:C	W63S	0.999
11:69641504:T:A	M64K	0.999
11:69641504:T:G	M64R	0.999
11:69641507:T:C	L65P	0.999
11:69643035:G:A	C68Y	0.999
11:69643036:C:G	C68W	0.999
11:69643065:T:C	F78S	0.999
11:69643073:G:C	A81P	0.999
11:69643074:C:A	A81D	0.999
11:69643089:A:C	D86A	0.999

dbSNP variants (sampled 300 via entrez): RS1000129111 (11:69643479 G>A,T), RS1000175513 (11:69645905 C>T), RS1000243204 (11:69640481 G>A), RS1000599947 (11:69650437 G>T), RS1000747310 (11:69650465 C>T), RS1001164563 (11:69653485 C>A,G), RS1001201091 (11:69650652 G>A), RS1001300235 (11:69653649 T>C), RS1001310794 (11:69650713 T>A,G), RS1001549565 (11:69651010 C>T), RS1001860592 (11:69648347 C>T), RS1002301084 (11:69654544 C>G), RS1002460228 (11:69649416 A>G), RS1002490314 (11:69642902 C>G,T), RS1002521017 (11:69642639 C>T)

Disease associations

OMIM: gene MIM:168461 | disease phenotypes: MIM:192500, MIM:114500, MIM:193300, MIM:254500

GenCC curated gene-disease

Disease	Classification	Inheritance
von Hippel-Lindau disease	Supportive	Autosomal dominant

Mondo (4): familial long QT syndrome (MONDO:0019171), colorectal cancer (MONDO:0005575), von Hippel-Lindau disease (MONDO:0008667), plasma cell myeloma (MONDO:0009693)

Orphanet (6): Romano-Ward syndrome (Orphanet:101016), Congenital long QT syndrome (Orphanet:768), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443), Von Hippel-Lindau disease (Orphanet:892), NON RARE IN EUROPE: Colorectal cancer (Orphanet:466667)

HPO phenotypes

94 total (30 of 94 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000014	Abnormality of the bladder
HP:0000098	Tall stature
HP:0000100	Nephrotic syndrome
HP:0000112	Nephropathy
HP:0000360	Tinnitus
HP:0000407	Sensorineural hearing impairment
HP:0000478	Abnormality of the eye
HP:0000541	Retinal detachment
HP:0000572	Visual loss
HP:0000739	Anxiety
HP:0000822	Hypertension
HP:0000938	Osteopenia
HP:0000975	Hyperhidrosis
HP:0000980	Pallor
HP:0001085	Papilledema
HP:0001095	Hypertensive retinopathy
HP:0001297	Stroke
HP:0001442	Typified by somatic mosaicism
HP:0001638	Cardiomyopathy
HP:0001658	Myocardial infarction
HP:0001737	Pancreatic cysts
HP:0001744	Splenomegaly
HP:0001824	Weight loss
HP:0001901	Polycythemia
HP:0001903	Anemia
HP:0001919	Acute kidney injury
HP:0001945	Fever
HP:0001962	Palpitations
HP:0002027	Abdominal pain

GWAS associations

45 associations (top):

Study	Trait	p-value
GCST000678_13	Breast cancer	3.000000e-15
GCST001585_32	Breast size	5.000000e-06
GCST001906_10	Multiple myeloma (IgH translocation)	2.000000e-11
GCST001906_15	Multiple myeloma (IgH translocation)	8.000000e-11
GCST002346_12	Breast cancer (early onset)	1.000000e-08
GCST002346_17	Breast cancer (early onset)	2.000000e-15
GCST002702_14	Height	1.000000e-11
GCST003061_13	Cutaneous malignant melanoma	3.000000e-07
GCST003061_6	Cutaneous malignant melanoma	2.000000e-12
GCST003985_11	Breast size	1.000000e-09
GCST004028_5	Immunoglobulin light chain (AL) amyloidosis	8.000000e-11
GCST004066_115	Hip circumference	4.000000e-08
GCST004066_42	Hip circumference	8.000000e-06
GCST004142_21	Melanoma	2.000000e-12
GCST004412_6	Craniofacial microsomia	4.000000e-17
GCST004988_266	Breast cancer	4.000000e-95
GCST004988_274	Breast cancer	6.000000e-47
GCST005348_100	Total body bone mineral density	1.000000e-08
GCST005348_203	Total body bone mineral density	4.000000e-09
GCST005588_2	Idiopathic dilated cardiomyopathy	7.000000e-06
GCST006988_62	Blond vs. brown/black hair color	4.000000e-13
GCST007094_211	Diastolic blood pressure	2.000000e-09
GCST007293_120	Body fat distribution (arm fat ratio)	4.000000e-06
GCST007293_22	Body fat distribution (arm fat ratio)	5.000000e-09
GCST007293_48	Body fat distribution (arm fat ratio)	5.000000e-12
GCST007505_22	Nevus count or cutaneous melanoma	1.000000e-06
GCST007847_68	Type 2 diabetes	1.000000e-06
GCST008362_4	Birth weight	9.000000e-12
GCST008363_84	Offspring birth weight	7.000000e-07
GCST009379_319	Type 2 diabetes	4.000000e-07

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0009094	idiopathic dilated cardiomyopathy
EFO:0003924	hair color
EFO:0006336	diastolic blood pressure
EFO:0004341	body fat distribution
EFO:0004632	nevus count
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0010059	cerebral microbleeds
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650
D006623	von Hippel-Lindau Disease	C10.562.925; C14.907.077.925; C16.131.077.245.750; C16.320.184.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (10): CHEMBL1907601 (PROTEIN COMPLEX), CHEMBL2095942 (PROTEIN COMPLEX GROUP), CHEMBL2111455 (PROTEIN COMPLEX), CHEMBL3610 (SINGLE PROTEIN), CHEMBL3885551 (PROTEIN COMPLEX), CHEMBL3885552 (PROTEIN COMPLEX), CHEMBL4523688 (PROTEIN-PROTEIN INTERACTION), CHEMBL5483183 (PROTEIN COMPLEX GROUP), CHEMBL6195584 (PROTEIN-PROTEIN INTERACTION), CHEMBL6195586 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

35 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 147,149 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL3545110	RIBOCICLIB	4	8,018
CHEMBL3894860	TRILACICLIB	4	2,086
CHEMBL2103840	DINACICLIB	3	2,257
CHEMBL3904602	LEROCICLIB	3	1,012
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL50	QUERCETIN	3	74,559
CHEMBL1276127	INDIRUBIN	2	181
CHEMBL14762	SELICICLIB	2	3,787
CHEMBL1738757	REBASTINIB	2	1,478
CHEMBL3115681	NARAZACICLIB	2	287
CHEMBL3545283	RIVICICLIB	2	968
CHEMBL384304	RG-547	2	93
CHEMBL3905910	VORUCICLIB	2	856
CHEMBL4067549	ULECACICLIB	2	41
CHEMBL4277900	CROZBACICLIB	2	18
CHEMBL4442620	RONICICLIB	2	367
CHEMBL4446357	EBVACICLIB	2	599
CHEMBL445813	AT-7519	2	2,614
CHEMBL5095060	ECIRUCICLIB	2
CHEMBL5095094	CULMERCICLIB	2
CHEMBL5187755	ATIRMOCICLIB	2
CHEMBL5199065	ISTISOCICLIB	2
CHEMBL5201870	TEGTOCICLIB	2
CHEMBL564829	MILCICLIB	2
CHEMBL6246	ELLAGIC ACID	2
CHEMBL1230607	PHA-793887	1
CHEMBL258805	SU-9516	1
CHEMBL296468	BMS-387032	1

Clinical evidence (CIViC)

Drug × variant × indication: 12 predictive associations from 13 curated evidence items; also 7 prognostic, 1 diagnostic.

Variant	Therapy	Indication	Effect	Level	CIViC
CCND1 Overexpression	Palbociclib	Mantle Cell Lymphoma	Sensitivity/Response	CIViC B	EID1536 +1
CCND1 Amplification	Sorafenib + Carboplatin + Paclitaxel	Skin Melanoma	Sensitivity/Response	CIViC B	EID1495
CCND1 Amplification	Palbociclib	Lung Squamous Cell Carcinoma	Sensitivity/Response	CIViC B	EID7405
CCND1 Amplification	Ribociclib	Cancer	Sensitivity/Response	CIViC B	EID7789
CCND1 Amplification OR CCND2 Amplification OR CCND3 Amplification	Palbociclib	Cancer	Sensitivity/Response	CIViC B	EID11673
CCND1 Amplification	Tamoxifen	Breast Cancer	Resistance	CIViC B	EID858
CCND1 Overexpression	Tamoxifen	Estrogen-receptor Positive Breast Cancer	Resistance	CIViC B	EID856
CCND1 Overexpression	Bortezomib	Multiple Myeloma	Sensitivity/Response	CIViC C	EID7788
CCND1 Amplification	Palbociclib	Renal Cell Carcinoma	Sensitivity/Response	CIViC D	EID1560
CCND1 Amplification	Palbociclib	Breast Cancer	Sensitivity/Response	CIViC D	EID1562
CCND1 Amplification	Palbociclib	Ovarian Cancer	Sensitivity/Response	CIViC D	EID1599
CCND1 Overexpression	Ribociclib	Anaplastic Thyroid Carcinoma	Sensitivity/Response	CIViC D	EID7790

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

6 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs9344	Efficacy	3	cetuximab	Colorectal Neoplasms
rs9344	Efficacy	3	cisplatin;doxorubicin;methotrexate	Osteosarcoma
rs9344	Efficacy	3	fluorouracil	Colonic Neoplasms
rs9344	Toxicity	3	methotrexate	Acute lymphoblastic leukemia;Lymphoma;Osteosarcoma
rs9344	Efficacy	3	methotrexate	Acute lymphoblastic leukemia

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs9344	CCND1	3	3.25	6	methotrexate;fluorouracil;cetuximab;cisplatin;doxorubicin;methotrexate

Binding affinities (BindingDB)

1139 measured of 2053 human assays (2116 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(3S,4S)-4-[[5-chloro-4-(5-fluoro-1,1-dimethyl-2,3-dihydropyrrolo[1,2-a]benzimidazol-7-yl)pyrimidin-2-yl]amino]-1-methylsulfonylpiperidin-3-ol	KI	0.1 nM	US-10766884: Cyclin dependent kinase inhibitors
8-Cyclopentyl-2-[4-(2-diethylaminoethoxy)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one	IC50	0.7 nM
2-[[(3S,5R)-3,5-dimethylmorpholin-4-yl]methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	0.8 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyrimidin-4-yl)-1,3-thiazol-2-amine	IC50	1 nM
4-[(4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-yl)amino]benzonitrile	IC50	1 nM
N-(3,4-dichlorophenyl)-4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-amine	IC50	1 nM
N-(3,5-difluorophenyl)-4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-amine	IC50	1 nM
2-[[(3S,5S)-3,5-dimethylmorpholin-4-yl]methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	1.1 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-2-[[(3R)-3-hydroxypiperidin-1-yl]methyl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	1.6 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-yl-2-pyrrolidin-2-ylquinolin-4-one	IC50	1.6 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-2-(7-oxa-4-azaspiro[2.5]octan-4-ylmethyl)-1-propan-2-ylquinolin-4-one	IC50	1.9 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
2-N-(1-methanesulfonylpiperidin-4-yl)-5-[(2,3,4-trifluoro-6-methoxyphenyl)carbonyl]pyrimidine-2,4-diamine	KI	2 nM
N-(2,6-Difluorophenyl)-N-[5-[[[5-tert-butyl-2-oxazolyl]-methyl]thio]-2-thiazolyl]urea	IC50	2 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyridin-2-yl)-1,3-thiazol-2-amine	IC50	2 nM
N-{4-[(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)amino]phenyl}-2-hydroxyethane-1-sulfonamido	IC50	2 nM
N-(3-methoxyphenyl)-4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-amine	IC50	2 nM
2-[1-(3-dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)maleimide	IC50	2.3 nM
2-[[(3R,5R)-3,5-dimethylmorpholin-4-yl]methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	2.7 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
2,4-Diamino-5-ketopyrimidine 39	KI	3 nM
3-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)-1-(2,6-dichlorophenyl)urea	IC50	3 nM
N-[5-[[[5-tert-Butyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-[[[bis(hydroxymethyl)methyl]amino]methyl]benzeneacetamide Hydrochloride Salt	IC50	3 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-(pyridin-3-yl)-1,3-thiazol-2-amine	IC50	3 nM
3-[({6-[(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)amino]pyridin-3-yl}methyl)amino]-2,2-dimethylpropan-1-ol	IC50	3 nM
N-(3,5-dimethylphenyl)-4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-amine	IC50	3 nM
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-2-(morpholin-4-ylmethyl)-1-propan-2-ylquinolin-4-one	IC50	3.4 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
(3S)-1-[[7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-4-oxo-1-propan-2-ylquinolin-2-yl]methyl]piperidine-3-carbonitrile	IC50	3.8 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
2-[(3,3-difluoropiperidin-1-yl)methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	3.9 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
(3R,4R)-3-methoxy-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	IC50	3.93 nM	US-10189849: CDK inhibitors
4-(2-tert-butyl-7-fluoro-3H-benzimidazol-5-yl)-5-fluoro-N-(1-methylpiperidin-4-yl)pyrimidin-2-amine	KI	4 nM	US-11220494: Cyclin dependent kinase inhibitors
N-[5-[[[5-(Cyclohexylmethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]acetamide	IC50	4 nM
5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-N-phenyl-1,3-thiazol-2-amine	IC50	4 nM
1-[3-(2,4-dimethyl-1,3-thiazol-5-yl)-4-oxo-2H,4H-indeno[1,2-c]pyrazol-5-yl]-3-(dimethylamino)urea	IC50	4 nM
8-cycloheptyl-2-({4-[2-(diethylamino)ethoxy]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one	IC50	4 nM
4-[(4-{imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]-N-(3-methoxypropyl)benzene-1-sulfonamide	IC50	4 nM
(3R)-1-[[7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-4-oxo-1-propan-2-ylquinolin-2-yl]methyl]piperidine-3-carbonitrile	IC50	4.1 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-2-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	4.1 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
(5R)-9-[[7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-4-oxo-1-propan-2-ylquinolin-2-yl]methyl]-2,9-diazaspiro[4.5]decan-1-one	IC50	4.1 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-2-[[(3S)-3-hydroxypiperidin-1-yl]methyl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	4.3 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
2-[(4,4-difluoropiperidin-1-yl)methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-1-propan-2-ylquinolin-4-one	IC50	4.7 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
2-[[(3R,5R)-3,5-dimethylmorpholin-4-yl]methyl]-7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-1-propan-2-ylquinolin-4-one	IC50	4.8 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
(5S,6R,7R,9R,16R)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one	IC50	5 nM
N-[5-[[(5-tert-Butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide	IC50	5 nM
N-[5-[[[5-tert-Butyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-2-isopropylamide	IC50	5 nM
N-[5-[[(5-Ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-1-isopropylamide	IC50	5 nM
N-[5-[[(5-Ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-3-pyridineacetamide	IC50	5 nM
N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)-2-(pyridin-3-yl)acetamide	IC50	5 nM
3-(4-Methoxyphenyl)-5-(dimethylaminocarbamoyl)aminoindeno[1,2-c]pyrazol-4-one	IC50	5 nM
9-[[7-[5-fluoro-2-[[(3S,4R)-3-hydroxyoxan-4-yl]amino]pyrimidin-4-yl]-3-methyl-4-oxo-1-propan-2-ylquinolin-2-yl]methyl]-2,9-diazaspiro[4.5]decan-1-one	IC50	5 nM	US-20250136586: Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
(2R)-2-cyclopropyl-2-[[9-(difluoromethyl)-6-[[(3R,4R)-4-fluoro-1-(1H-imidazol-2-ylsulfonyl)pyrrolidin-3-yl]amino]purin-2-yl]amino]ethanol	IC50	5 nM	US-20250197425: 2,6,9-TRISUBSTITUTED PURINES
N-[2-(dimethylamino)ethyl]-4-[(4-{imidazo[1,2-a]pyridin-3-yl}pyrimidin-2-yl)amino]benzene-1-sulfonamide	IC50	5 nM

ChEMBL bioactivities

2964 potent at pChembl≥5 of 3252 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	Ki	0.01	nM	CHEMBL4444429
10.40	Ki	0.04	nM	CHEMBL4468645
10.33	Ki	0.047	nM	CHEMBL5272948
10.22	Ki	0.06	nM	TAPOTOCLAX
10.22	Ki	0.06	nM	CHEMBL5817327
10.19	Ki	0.064	nM	CHEMBL5281860
10.15	Ki	0.07	nM	CHEMBL4465718
10.10	Ki	0.08	nM	EBVACICLIB
10.10	Ki	0.08	nM	CHEMBL5994083
10.00	IC50	0.1	nM	CHEMBL5198209
10.00	Ki	0.1	nM	CHEMBL5266837
10.00	Ki	0.1	nM	CHEMBL5795283
10.00	Ki	0.1	nM	CHEMBL5799855
10.00	Ki	0.1	nM	CHEMBL5805872
10.00	Ki	0.1	nM	CHEMBL5876670
10.00	Ki	0.1	nM	CHEMBL6001085
10.00	Ki	0.1	nM	CHEMBL5882519
10.00	Ki	0.1	nM	CHEMBL6001033
10.00	Ki	0.1	nM	CHEMBL5749795
10.00	Ki	0.1	nM	CHEMBL6052225
10.00	Ki	0.1	nM	CHEMBL5907078
10.00	Ki	0.1	nM	CHEMBL5783305
10.00	Ki	0.1	nM	CHEMBL6026426
10.00	Ki	0.1	nM	CHEMBL5786491
9.96	Ki	0.11	nM	EBVACICLIB
9.96	Ki	0.11	nM	CHEMBL5833205
9.92	Ki	0.12	nM	CHEMBL5774115
9.89	Ki	0.13	nM	CHEMBL4750658
9.89	Ki	0.13	nM	CHEMBL5746772
9.89	Ki	0.13	nM	CHEMBL5281770
9.89	Ki	0.13	nM	CHEMBL6047972
9.89	Ki	0.13	nM	CHEMBL5281860
9.85	Ki	0.14	nM	CHEMBL5764489
9.85	Ki	0.14	nM	CHEMBL5866256
9.82	Ki	0.15	nM	CHEMBL5789495
9.77	Ki	0.17	nM	CHEMBL5857212
9.74	Ki	0.18	nM	CHEMBL4745424
9.74	Ki	0.18	nM	CHEMBL5942490
9.72	Ki	0.19	nM	CHEMBL5281860
9.72	Ki	0.19	nM	CHEMBL5269912
9.72	Ki	0.19	nM	CHEMBL5833205
9.71	Ki	0.196	nM	CHEMBL5278015
9.70	Ki	0.2	nM	CHEMBL5280928
9.70	Ki	0.2	nM	PALBOCICLIB
9.70	Ki	0.2	nM	CHEMBL5921011
9.70	Ki	0.2	nM	CHEMBL6041338
9.70	Ki	0.2	nM	CHEMBL5982367
9.70	Ki	0.2	nM	CHEMBL5982735
9.70	Ki	0.2	nM	CHEMBL5851399
9.70	Ki	0.2	nM	CHEMBL5960728

PubChem BioAssay actives

2272 with measured affinity, of 3746 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3’R,4S,6’R,7’S,8’E,12’R)-7-chloro-7’-hydroxy-12’-methyl-13’,13’-dioxospiro[2,3-dihydro-1H-naphthalene-4,22’-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15’-one	2122674: Binding affinity to human BCL1 assessed as inhibition constant	ki	<0.0001	uM
8-cyclopentyl-6-methyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	<0.0001	uM
(4S)-7-chloro-11’,11’-dioxospiro[2,3-dihydro-1H-naphthalene-4,20’-8,18-dioxa-11lambda6-thia-1,12-diazatricyclo[12.7.2.017,22]tricosa-14(23),15,17(22)-triene]-13’-one	2122674: Binding affinity to human BCL1 assessed as inhibition constant	ki	<0.0001	uM
(3’R,4S,6’R,7’S,12’R)-7-chloro-7’-hydroxy-12’-methyl-13’,13’-dioxospiro[2,3-dihydro-1H-naphthalene-4,22’-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-16(25),17,19(24)-triene]-15’-one	2122674: Binding affinity to human BCL1 assessed as inhibition constant	ki	0.0001	uM
(3’R,4S,6’R,7’S,8’E,11’S,12’R)-7-chloro-7’-methoxy-11’,12’-dimethyl-13’,13’-dioxospiro[2,3-dihydro-1H-naphthalene-4,22’-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15’-one	2122674: Binding affinity to human BCL1 assessed as inhibition constant	ki	0.0001	uM
6-(2,2-difluoroethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0001	uM
6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0001	uM
6-(2,2-difluoroethyl)-8-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0001	uM
2-(2-ethylphenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0001	uM
8-cyclopentyl-6-(cyclopropyloxymethyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0001	uM
8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-6-methyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
2-[8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]-7-oxopyrido[2,3-d]pyrimidin-6-yl]acetonitrile	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0002	uM
8-cyclopentyl-6-(2-methoxyethyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
8-cyclopentyl-6-(hydroxymethyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
8-cyclopentyl-6-(ethoxymethyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
6-acetyl-8-cyclopentyl-5-methyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
Palbociclib	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0002	uM
5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)-N-(5-piperazin-1-yl-2-pyridinyl)pyrimidin-2-amine	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0003	uM
2-[8-cyclopentyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]-7-oxopyrido[2,3-d]pyrimidin-6-yl]acetonitrile	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0003	uM
6-chloro-8-cyclopentyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0003	uM
N-[5-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-2-pyridinyl]-5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-amine	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0003	uM
5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)-N-(5-piperidin-4-yl-2-pyridinyl)pyrimidin-2-amine	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0004	uM
6-chloro-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0004	uM
Abemaciclib	2198996: Inhibition of human CDK6/cyclin D1 preincubated with compound for 20 mins followed by [33P]ATP addition and measured after 2 hrs by filter binding method	ic50	0.0004	uM
8-cyclohexyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0005	uM
8-cyclopentyl-6-(2-hydroxyethyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0005	uM
[4-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]amino]-3-pyridinyl]piperazin-2-yl]methanol	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0006	uM
8-cycloheptyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0006	uM
N-[5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-pyridinyl]-5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-amine	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0006	uM
2-(4-chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0006	uM
2-(2-bromophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0006	uM
8-cyclopentyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0007	uM
8-cyclopentyl-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidin-7-one	1795862: CDKs Assay from Article 10.1021/jm000271k: “Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.”	ic50	0.0007	uM
N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-amine	2107973: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0008	uM
8-[(1R,2S)-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1933532: Inhibition of CDK4/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0008	uM
8-[(1R,2S,3R)-3-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0008	uM
5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2-pyridin-4-yl-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0008	uM
5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2-(3-methylphenyl)-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0008	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2,3-dihydrochromen-4-one	1868057: Inhibition of CDK4/Cyclin D1 (unknown origin)	ic50	0.0008	uM
N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide	1489811: Inhibition of human CDK4/Cyclin D1 using RB protein as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition measure after 120 mins by filter binding method	ic50	0.0008	uM
2-[[1-(cyclopropylmethylsulfonyl)piperidin-4-yl]amino]-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]pyrido[2,3-d]pyrimidin-7-one	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0009	uM
8-cyclopentyl-2-[(1-methylsulfonylpiperidin-4-yl)amino]-6-(propan-2-yloxymethyl)pyrido[2,3-d]pyrimidin-7-one	1933533: Inhibition of CDK6/cyclin D1 (unknown origin) assessed as reduction in substrate peptide phosphorylation using DYRKtide peptide as substrate preincubated for 12 mins followed by ATP addition and measured for 45 mins by mobility shift assay	ki	0.0009	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3,4-trifluoro-6-methoxyphenyl)methanone	1796919: Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1021/jm0606138: “Discovery of 4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-ylmethanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.”	ki	0.0010	uM
N-cyclopentyl-4-methyl-5-[2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrimidin-4-yl]-1,3-thiazol-2-amine	1438404: Inhibition of CDK4/cyclin D1 (unknown origin) in presence of [gamma-33P]-ATP by KINOMEscan assay	ki	0.0010	uM
N-cyclopentyl-5-[2-[[5-[4-(dimethylamino)piperidin-1-yl]-2-pyridinyl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine	1438404: Inhibition of CDK4/cyclin D1 (unknown origin) in presence of [gamma-33P]-ATP by KINOMEscan assay	ki	0.0010	uM
N-cyclopentyl-5-[2-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]pyrimidin-4-yl]-4-(trifluoromethyl)-1,3-thiazol-2-amine	1438404: Inhibition of CDK4/cyclin D1 (unknown origin) in presence of [gamma-33P]-ATP by KINOMEscan assay	ki	0.0010	uM
4-[[6-chloro-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-N-methylpiperidine-1-sulfonamide	1685180: Inhibition of non-phosphorylated CDK6/Cyclin D1 (unknown origin) assessed as reduction in production of ADP using 5-FAM-RRRFRPASPLRGPPK peptide as substrate preincubated with enzyme for 12 mins and measured after 35 mins in presence of ATP by fluorescence-based microfluidic mobility shift assay	ki	0.0010	uM
N-cyclopentyl-5-[2-[[5-(1,4-diazepan-1-yl)-2-pyridinyl]amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine	1438404: Inhibition of CDK4/cyclin D1 (unknown origin) in presence of [gamma-33P]-ATP by KINOMEscan assay	ki	0.0010	uM
N-cyclopentyl-5-[5-fluoro-2-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine	1438404: Inhibition of CDK4/cyclin D1 (unknown origin) in presence of [gamma-33P]-ATP by KINOMEscan assay	ki	0.0010	uM
8-cyclopentyl-2-(3-fluoro-4-piperazin-1-ylanilino)quinazolin-7-ol	1795879: CDKs Assay from Article 10.1016/j.bmcl.2005.05.131: “2-Aminoquinazoline inhibitors of cyclin-dependent kinases.”	ic50	0.0010	uM

CTD chemical–gene interactions

785 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, affects expression, affects binding, increases response to substance (+6 more)	68
Resveratrol	affects reaction, affects activity, affects expression, affects binding, decreases activity (+6 more)	52
sodium arsenite	increases expression, decreases reaction, affects binding, increases reaction, increases abundance (+4 more)	34
Arsenic Trioxide	decreases reaction, increases expression, increases reaction, increases activity, decreases response to substance (+10 more)	29
Curcumin	decreases reaction, affects cotreatment, increases expression, increases degradation, increases reaction (+1 more)	25
bisphenol A	increases reaction, affects expression, decreases expression, affects binding, affects folding (+3 more)	24
Fulvestrant	affects cotreatment, increases expression, affects expression, decreases expression, decreases reaction	24
Quercetin	decreases reaction, increases reaction, affects expression, affects binding, affects reaction (+3 more)	19
Tamoxifen	affects binding, affects reaction, affects cotreatment, affects expression, increases expression (+3 more)	18
Cadmium Chloride	increases abundance, affects reaction, decreases reaction, increases expression, affects cotreatment (+4 more)	17
U 0126	affects reaction, increases abundance, decreases activity, decreases reaction, increases expression (+4 more)	14
Benzo(a)pyrene	decreases reaction, affects reaction, decreases expression, affects methylation, affects cotreatment (+2 more)	13
Lithium Chloride	affects localization, increases degradation, decreases activity, decreases phosphorylation, increases expression (+5 more)	13
Tretinoin	increases expression, increases ubiquitination, decreases expression, increases degradation, decreases response to substance (+4 more)	12
Sorafenib	increases reaction, affects cotreatment, decreases reaction, increases expression, decreases expression	11
Genistein	affects cotreatment, decreases expression, affects expression, affects reaction, increases abundance (+2 more)	11
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases reaction, increases degradation, decreases phosphorylation, increases expression, decreases expression	10
Troglitazone	affects response to substance, decreases expression, decreases activity, increases response to substance, increases degradation (+1 more)	10
Vorinostat	decreases reaction, increases abundance, increases reaction, increases expression, affects cotreatment (+1 more)	10
Acetylcysteine	decreases reaction, increases expression, affects cotreatment, decreases expression, increases phosphorylation	10
Arsenic	affects response to substance, affects reaction, increases expression, affects expression, affects cotreatment (+3 more)	10
Cadmium	affects expression, affects reaction, decreases reaction, affects cotreatment, affects binding (+4 more)	10
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	decreases reaction, increases expression, decreases expression, increases reaction	9
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	decreases reaction, increases expression, increases abundance, decreases expression, increases phosphorylation (+2 more)	9
Aspirin	decreases reaction, increases expression, decreases expression, affects reaction	9
Niclosamide	decreases expression, decreases reaction, increases expression, increases reaction	9
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases reaction, increases expression, increases reaction, increases response to substance, affects cotreatment (+1 more)	8
(+)-JQ1 compound	affects cotreatment, decreases reaction, decreases expression, affects binding	8
Cisplatin	affects cotreatment, decreases expression, increases expression, increases reaction, affects binding (+2 more)	8
Indomethacin	increases expression, affects cotreatment, decreases expression, affects binding, decreases reaction	8

ChEMBL screening assays

576 unique, capped per target: 574 binding, 1 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1016197	Binding	Inhibition of CDK4/Cyclin D1 assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation	Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4. — J Med Chem
CHEMBL666092	Functional	Inhibition of Rb21 phosphorylation by Cyclin D1-cyclin-dependent kinase 4	Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. — Bioorg Med Chem Lett
CHEMBL4313023	ADMET	Induction of CRBN-mediated CCND1 degradation in human U251 cells at 500 nM after 4 hrs by immunoblot analysis	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. — J Med Chem

Cellosaurus cell lines

65 cell lines: 46 telomerase immortalized cell line, 10 cancer cell line, 9 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1699	SK-MM-2	Cancer cell line	Male
CVCL_A5XS	AM-3	Telomerase immortalized cell line	Female
CVCL_B1MK	Abcam HeLa CCND1 KO 1	Cancer cell line	Female
CVCL_B1ML	Abcam HeLa CCND1 KO 2	Cancer cell line	Female
CVCL_B3M3	T21-KC-K4DT	Telomerase immortalized cell line	Female
CVCL_B3Q5	NP361-cyclinD1-hTert	Telomerase immortalized cell line	Female
CVCL_B3Q7	NP446-cyclinD1-hTert	Telomerase immortalized cell line	Female
CVCL_B3Q9	NP550-cyclinD1-hTert	Telomerase immortalized cell line	Male
CVCL_B6FC	HepZ	Transformed cell line	Sex unspecified
CVCL_B7I4	AIA1	Telomerase immortalized cell line	Male

Clinical trials (associated diseases)

345 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT00114829	PHASE4	UNKNOWN	Preoperative Assessment of Colon Tumor
NCT00114842	PHASE4	COMPLETED	Magnetic Resonance (MR) Colonography With Fecal Tagging
NCT00114946	PHASE4	TERMINATED	A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00122720	PHASE4	COMPLETED	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
NCT00129870	PHASE4	TERMINATED	CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00138060	PHASE4	COMPLETED	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00216424	PHASE4	TERMINATED	Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00327093	PHASE4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00332943	PHASE4	COMPLETED	MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil
NCT00441311	PHASE4	COMPLETED	Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00460837	PHASE4	WITHDRAWN	Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
NCT00473980	PHASE4	COMPLETED	Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00488904	PHASE4	COMPLETED	Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00502671	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
NCT00559676	PHASE4	COMPLETED	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031	PHASE4	COMPLETED	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00626054	PHASE4	COMPLETED	Comparison of Two Methods of Administration of a PEG Solution
NCT00812864	PHASE4	COMPLETED	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00868569	PHASE4	UNKNOWN	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
NCT00868816	PHASE4	COMPLETED	Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
NCT00874406	PHASE4	UNKNOWN	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00928928	PHASE4	COMPLETED	Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer
NCT00942461	PHASE4	COMPLETED	Inflammatory Response in Laparoscopic and Open Colectomy
NCT01023633	PHASE4	UNKNOWN	OPTIMOX1 in Chinese mCRC Patients
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01315990	PHASE4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01493713	PHASE4	COMPLETED	Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01609660	PHASE4	COMPLETED	Impact of Probiotics on the Intestinal Microbiota
NCT01641458	PHASE4	COMPLETED	Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
NCT01689792	PHASE4	COMPLETED	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
NCT01695772	PHASE4	COMPLETED	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01695863	PHASE4	COMPLETED	Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
NCT01706822	PHASE4	TERMINATED	Radial Reload Laparoscopic LAR Case Series
NCT01740947	PHASE4	TERMINATED	Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?
NCT01831310	PHASE4	COMPLETED	Nutrition for Colorectal Cancer Patients and Neutrophil Functions